Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vixotrigine in Primary Inherited Erythromelalgia
NCT02917187Phase 2Completed
- Sponsor
- Biogen
- Start
- Sep 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vixotrigine in primary erythromelalgia (PE) (2 arms), sponsored by Biogen. Primary endpoint: Weekly average severity of paroxysms. Started Sep 2016; status: completed.
02
Drugs
vixotrigine
03
Conditions
primary erythromelalgia (PE)
Beyond the preview
Go deeper on NCT02917187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02917187.